Essential universal health coverage needs local capacity development

Citation for published version:

Digital Object Identifier (DOI):
10.1016/S2214-109X(20)30224-2

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published in:
The Lancet Global Health

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Essential universal health coverage needs local capacity development

Disease Control Priorities, 3rd edition (DCP3), published in 2017, reanimated academic debate about the value of cost-effectiveness and global knowledge in priority setting for national health policy. In 1993, the first DCP project was published by Jamison and his team with the support of the World Bank to define health as an investment rather than an expenditure at the international and national levels. DCP1 and DCP2, which was published in 2006, both substantially influenced the ways in which the World Bank, WHO, and other global health donors prioritised investment in health interventions in low-income countries (LICs) and lower-middle-income countries (lower-MICs), but they had insufficient uptake by the governments in these countries. This lack of uptake was partly due, as critics of DCP1 and DCP2 argued, to an overemphasis on the economic evaluation of health interventions over other important factors, including health equity. Furthermore, insufficient attention was given to the technical capacity required to interpret DCP data and translate it into local health policy.

In response to these critiques, and to update the DCP in alignment with the Sustainable Development Goals, DCP3 was produced with the aim that it would be most useful for ministers of finance in LICs and lower-MICs. Although DCP3 does expand beyond cost-effectiveness to include other objectives such as financial protection, palliative care, and contraception needs, the report prompted further reflection on the role of economic evaluation in health policy making. As the field of health economics has expanded in the past few decades, rapid advances in the development of health economic tools have paradoxically made such tools less useful for decision makers. Therefore, future versions of the DCP should emphasise health-care needs at the national and local levels, and highlight the importance of country-level technical capacity to understand these needs. This strengthened technical capacity to interpret and contextualise DCP evidence at the country level should also be paired with reporting and use of direct mortality data rather than modelled data.

In this context, David Watkins and colleagues have produced a modelling study and an online costing tool—the Disease Control Priorities Cost Model (DCP-CM)—as starting points to help countries prioritise their health packages and achieve what the authors of DCP3 term essential universal health coverage (EUHC). The team has produced cost estimates for the 218 health interventions that comprise the 21 packages of EUHC, and for the 112 interventions within these that comprise a highest priority package in DCP3. The cost estimates are for two stylised countries standing in for LICs and lower-MICs, using the World Bank criteria to define these income groups.

Their study and the online costing tool are invaluable for health financing advocacy—both make clear the need for increased domestic and global financial resources, via modelling the cost of implementing even minimum versions of UHC for countries in the midst of epidemiological transition. Furthermore, DCP-CM undoubtedly provides an important starting point for ministers of finance and health to build budgets for robust national health systems. However, as tools for prioritising interventions in national health policy, this study and the DCP-CM should be accompanied by extensive country-level expertise on actual costs of health interventions and local data on disease burden, alongside other, non-economic forms of evaluation. They provide a reminder of the importance of investing in local capacity development beyond short-term engagement or knowledge produced in a global context. As many researchers have reiterated, building health policy for UHC in LICs and lower-MICs should attend not only to economic evaluation, but also to local values and contexts, the issue of health equity, and investment in local capacity development.

I declare no competing interests. I am supported by a grant from the European Research Council under the EU Horizon 2020 research and innovation programme (grant number 715125).

Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Marlee Tichenor
marlee.tichenor@ed.ac.uk
School of Social and Political Science, Chrystal Macmillan Building, The University of Edinburgh, Edinburgh EH8 9LD, UK
Comment


